Introduction

Auditory verbal hallucinations (AVH)—vocal perceptions in the absence of an actual auditory stimulus [1]—are one of the most common positive symptoms in schizophrenia. Recent findings from brain imaging have associated AVH with alterations in a brain network related to speech and language processing [2]. Alterations in connectivity patterns have been suggested to relate to current concepts of the emergence of AVH, such as the interhemispheric miscommunication hypothesis [3]. In this context, alterations in high-frequency (30–100 Hz) gamma-band oscillations (GBO) are consistently discussed [4], given their role in synchronizing neural activity within and between distributed brain structures. Although it is known that GBO have a specific role for perception processes in general [5, 6], and that alterations of GBO are a consistent finding in schizophrenia [4], our understanding of their role for AVH is still far from sufficient.

According to the interhemispheric miscommunication hypothesis, altered connectivity between bilateral auditory areas contributes to the underlying neural correlate of AVH. The hypothesis is based on multimodal evidence including diffusion tensor imaging (DTI), functional magnetic resonance imaging (fMRI) and electroencephalography (EEG) findings. DTI studies have shown that alterations of interhemispheric auditory pathways (IAP) are related to the appearance of AVH [7,8,9]. In addition, disturbed functional connectivity in the IAP have been found to be related to AVH using fMRI [10]. Moreover, a significant positive correlation was found between AVH severity and increased interhemispheric gamma-band coupling between bilateral auditory cortices [11]. Recently, Steinmann et al. [12] showed that AVH in schizophrenia are related to stronger interhemispheric gamma-band connectivity (lagged phase synchronization) during conscious perception of the left ear (LE) syllable in a dichotic listening (DL) task.

In healthy subjects, interhemispheric communication is relevant to conscious auditory perception in a DL task. Although both ears are connected anatomically via ipsilateral and contralateral pathways with the auditory cortices, ipsilateral pathways are suggested to be blocked during DL [13] leading to supremacy of contralateral pathways. Accordingly, auditory speech stimuli presented to the LE initially access the right hemisphere, but require further transfer across the corpus callosum (CC) to be efficiently processed in the speech-dominant left hemisphere [14] (Fig. 1a). This interhemispheric auditory transfer has been shown to be mediated by synchronized GBO [15], and further, to be particularly increased in schizophrenia patients hearing voices [12].

Fig. 1
figure 1

a Schematic illustration of the dichotic listening (DL) procedure, demonstrating the requirement of interhemispheric transfer when participants consciously perceive the auditory stimulus presented to the left ear (LE). Two different syllables are presented simultaneously: one to the right ear (GA) and one to the left ear (DA). Although both ears are connected anatomically via ipsilateral and contralateral pathways with the auditory cortices, ipsilateral pathways are suggested to be blocked during dichotic listening. The blue line indicates the contralateral pathway connecting the stimulus presented to the right ear (RE) directly with the speech-dominant left hemisphere. In contrast, the syllable arriving from the LE to the right hemisphere requires interhemispheric transfer via the corpus callosum (CC) to be efficiently processed (red line). Yellow: right and left auditory cortices, LH: left hemisphere, RH: right hemisphere. b Regions-of-interests (ROIs) within the left and right primary auditory cortices (PACs, BA41, red) and the left and right secondary auditory cortices (SACs, BA42, green). BA41-ROI covered a region extended from x: 35 to 55 and −35 to −55, y: −15 to −40, z: 5 to 15 and included all voxels of BA41. BA42-ROI covered a region extended from x: 55 to 70 and −55 to −65, y: −10 to −35, z: 5 to 20 and included all voxels of BA42

Gamma rhythms are dependent on the activity of parvalbumin-containing (PV) gamma-aminobutyric acid-(GABA-)ergic cortical inhibitory interneurons, which are subject to glutamate N-methyl-d-Aspartate receptor (NMDAR) modulation from excitatory pyramidal cells [16]. As disturbed gamma rhythms have been reported in schizophrenia consistently [17, 18], there has been growing interest in the role of inhibitory interneurons and their neural circuits that are responsible for maintaining a precise excitatory-to-inhibitory (E/I) balance [19]. Recent reviews have suggested that an impaired E/I balance is crucially involved in schizophrenia [20,21,22] and in the emergence of AVH [23]. Moreover, phase synchronization of oscillatory activity depends on E/I balance [23], and has been shown to be increased in the gamma-band between bilateral auditory cortices in schizophrenia patients with AVH [11]. Furthermore, NMDAR antagonists such as ketamine induce an E/I imbalance [24], and are known to alter GBO [25] and to elicit schizophrenia-like symptoms, including AVH [26,27,28], depending on the ketamine dose, in healthy volunteers. Whereas low doses (0.003 mg/kg/min) of ketamine already produce milder symptoms such as reduced vigilance, only high doses of ketamine (at least 0.005 mg/kg/min) are able to elicit auditory alterations [29]. This could be interpreted as evidence for a threshold dose to induce hallucinatory activity which is capable of disturbing the auditory perceptual system.

Given that increased GBO during LE percepts in a DL task are associated with AVH in schizophrenia patients, and that ketamine induces schizophrenia-like symptoms and influences GBO, we hypothesized that high-dose ketamine administered to healthy volunteers (1) elicits schizophrenia-like symptoms including AVH, (2) alters interhemispheric gamma-band connectivity during LE percepts, and that (3) enhanced interhemispheric gamma-band connectivity is particularly related to the occurrence of ketamine-induced auditory verbal distortions and hallucinations (AVD/AVH).

Materials and methods

Participants

Participants were recruited from the community through advertisement and word-of-mouth. Overall, 25 male German native speakers were enrolled in this study, who were either medical students or medical staff of the University Medical Center Hamburg. Inclusion criteria were male gender, age between 18 and 40 years, right-handedness, normal or corrected visual acuity, German at native speaker level, and normal hearing. Two of the volunteers dropped out due to adverse effects (dissociative effect/headache) during the ketamine session and were not able to continue with testing. Two further participants withdrew consent shortly before the first session. Two further participants did not fulfill criteria for further EEG analysis, i.e., <30 segments remained in one of the conditions (right ear (RE) or LE reports) after EEG pre-processing. For the following data analysis 19 subjects with a mean age of 25 years (SD = 2.32, range = 20–29) were included. The sample of the study is part of a larger project, of which some results have been published already [30].

All subjects were screened with pure tone audiometry for the frequencies of 120, 250, 500, 1000, 2000, 4000, and 8000 Hz (Esser Home Audiometer 2.0) in order to ensure normal hearing in both ears. Participants with an auditory threshold higher than 20 dB, or an interaural difference larger than 15 dB in any of the frequencies were excluded from the study. All volunteers were right-handed, assessed with the empirically validated Edinburgh Handedness Inventory [31] (mean = 84.55, SD = 16.19, range = 40–100). Exclusion criteria were the use of illicit drugs, alcohol consumption of more than seven units per week, current medication, a positive family history of schizophrenia or bipolar disorder, acute or past psychiatric disorders—tested with the Mini International Neuropsychiatric Interview [32] and the Schizotypal Personality Questionnaire (SPQ) [33]—cardiovascular diseases, hyperthyroidism and hypothyroidism, and a ketamine intolerance. All participants had normal IQ as tested with a vocabulary test [34] (mean = 112.00, SD = 5.58, range = 99–122). The general procedure was approved by the ethical committee of Medical Association Hamburg. After participants received a complete description of the experimental procedure, written informed consent was obtained according to the Declaration of Helsinki.

Study design

We used a single-blind, randomized, placebo-controlled crossover study design. During the ketamine session a subanesthetic dose of S-ketamine Hydrochloride (Ketanest® S - Pfizer) was administered intravenously in 0.9% sodium chloride (NaCl) solution using a syringe pump (Perfusor®Space) for 75 min. The ketamine infusion was started with an initial bolus of 10 mg over 5 min followed by a maintenance infusion of 0.006 mg/kg/min. As ketamine plasma levels slowly increase with continuous infusion, the dosage was reduced by 10% every 10 min. Placebo was administered analogously as 0.9% NaCl infusion. Heart rate, blood pressure and oxygen saturation were continuously monitored during both sessions by a board certified anesthesiologist. After both sessions the subjects stayed under constant supervision for one hour, until all drug effects had worn off.

Psychometric assessment

Psychiatric symptomatology was assessed using the Positive and Negative Syndrome Scale (PANSS) [35], including one item detecting hallucinations (P3) in any sensory modality (visual, olfactory, somatic and auditory). Prior to the first intervention (baseline) and after both drug challenges (placebo/ketamine) psychopathological evaluation was conducted by an experienced psychiatrist. PANSS scores were evaluated using the five-factor model by van der Gaag et al. [36].

To assess the subjective effects of ketamine and to detect auditory hallucinations specifically, the Altered State of Consciousness (5D-ASC) questionnaire [37], a visual analog scale, was used after both drug challenges (ketamine/placebo). This self-rating questionnaire consists of 94 items/statements assessing five key dimensions of altered states of consciousness (ASC): dread of ego dissolution (DED), auditory alterations (AUA), oceanic boundlessness (OBN), vigilance reduction (VIR), and visionary restructuralization (VRS). The scale was previously shown to be sensitive to the psychological effects of ketamine [27]. With respect to AVH in schizophrenia, we derived a more specific AUA subscore that included only AUA related to auditory verbal distortions (AVD) and AVH (AUA-AVD/AVH) in contrast to non-verbal auditory distortions and hallucinations. The AUA score includes 16 items of the 5D-ASC (items: 4, 5, 11, 13, 19, 25, 30, 48, 49, 55, 65, 66, 74, 76, 92, and 93), the AUA-AVD/AVH scores includes 6 items (4, 13, 19, 25, 30, and 65). Items were only included in the AUA-AVD/AVH score, if their corresponding statements contained the words “voice/s” “to speak” and/or “words”. For further details see Table S1. The participants were carefully assigned according to the current history of AVD and/or AVH under ketamine using the AUA-AVD/AVH score into two groups (AVD/AVH vs. non-AVD/AVH). This results in a non-AVD/AVH group of 10 participants who reported AUA-AVD/AVH on a level comparable to placebo, and in an AVD/AVH group of nine participants. Scores of the single items of the AUA-AVD/AVH score of both groups and placebo are shown in Figure S1.

Stimuli

The Bergen dichotic listening (DL) paradigm consists of six consonant-vowel (CV) syllables /ba/, /da/, /ga/, /pa/, /ta/ and /ka/, which were paired and presented simultaneously (Fig. 1a). All syllables were spoken by a German male speaker with constant intensity and intonation and with duration of 400–500 ms. Participants were instructed to report after each trial the syllable which was perceived. The response was given via button press with the right dominant hand. On the behavioral level a laterality index (LI), error rates and reaction times were evaluated. For detailed description see Steinmann et al. [15].

Recording and pre-processing

EEG recording took place in a sound-attenuated and electrically shielded cabin. Continuous EEG activity was recorded using Ag/AgCl electrodes mounted in a 64 channel actiCAP system (recording apparatus: Brain Products GmbH, Munich, Germany). EEG pre-processing was carried out using the Brain Vision Analyzer software version 2.0 (Brain Products, Munich, Germany). For detailed description see Steinmann et al. [15] and Supplementary Materials and Methods. After EEG pre-processing, trials were divided according to RE or LE percept. For all segments, 200 ms pre-stimulus to 1848 ms post-stimulus periods were created. The number of EEG segments used for analysis was balanced between LE and RE reports for every single subject resulting in a mean number of 76.95 (SD = 20.09) segments for each of the conditions. For the analyses of the N100 potential, auditory-evoked gamma-band response (aeGBR) and baseline gamma power see Supplementary Materials and Methods.

Functional connectivity analysis

All further analyses were executed with the LORETA KEY software package as provided by Roberto Pascual-Marqui (The KEY Institute for Brain-Mind Research University Hospital Psychiatry, Zurich) at www.uzh.ch/keyinst/LORETA.html. The eLORETA method is a discrete, three-dimensional (3D) distributed, linear, and weighted minimum norm inverse solution that has the property of exact localization to test point sources [38, 39].

For analysis of functional connectivity between auditory cortices the lagged phase synchronization (LPS) approach was applied. This method measures the similarity between signals in the frequency domain based on normalized (unit module) Fourier transforms, and thus, is related to nonlinear functional connectivity [40, 41]. For further details see Supplementary Materials and Methods.

In this study LPS was assessed within two a priori defined regions-of-interests (ROIs), which have been identified as essential nodes in the AVH network [15]: right and left primary (PACs/BA41) and secondary (SACs/BA42) auditory cortices (Fig. 1b). The ROIs were defined using the anatomical definitions based on the Talairach Daemon (http://www.talairach.org//). As a previous study by Steinmann et al. [15] did not find LPS differences in any other frequencies than gamma, we focused on the whole gamma-band range (30–100 Hz). LPS across all the voxels included in the ROIs was based on the average of all LPS values, which were calculated for the connectivity between every voxel of each ROI. For all single trials, time-varying frequency analysis was done using a short time Fourier transform (sliding Bartlett–Hann window function) with a window width of 100 ms. LPS was calculated using cross spectra derived from that transformation. Results were extracted every 100 ms in a time frame from 0 to 900 ms after stimulus presentation. In order to ensure that no baseline correction is required, LPS results were additionally extracted in the pre-stimulus baseline from 200 to 0 ms.

Statistics

All data analyses were performed using SPSS version 21. Behavioral data of DL task performance (LI, reaction times and error rates) between placebo and ketamine condition were conducted using paired-sample t-tests. Comparisons of 5D-ASC scores between placebo and ketamine condition, and further, between the AVD/AVH and non-AVD/AVH group, were conducted using paired-sample t-tests. To test the reliability of the AUA-AVD/AVH score, we analyzed internal consistency measured with Cronbach’s α. PANSS scores were analyzed by means of one-way repeated measure analysis of variance (RM-ANOVA) with condition (baseline, placebo, and ketamine) as within-subject factor and post-hoc t-tests. Bonferroni correction was applied for multiple comparisons. Spearman’s correlation coefficient was used in order to investigate the relation between gamma connectivity (mean LPS difference between ketamine and placebo for LE reports) and the AUA-AVD/AVH score. The effects of substance, condition, ROI and time on gamma connectivity were assessed with a linear mixed-effects model. Linear mixed models (LMM) have several advantages over traditional repeated-measures designs, as they can accommodate departures from the assumptions of homogeneity of regression slopes and independence, and thus, are better suited to model interindividual variability [42]. This model has also been successfully implemented by researchers to analyze EEG data [43, 44]. In this study, the model included Substance  (2 levels: placebo, ketamine), Condition (2 levels: LE and RE reports), ROI (2 levels: BA41, BA42) and Time(10 levels: from 0 to 900 ms in 100 ms steps) as the fixed-effects factors, subject as a random-effects factor, and Gamma Connectivity as the dependent variable. In follow-up analyses Group  (2 levels: AVD/AVH and non-AVD/AVH subjects) was included in order to differentiate more precisely between subjects with and without AVD/AVH under ketamine administration. LMM analysis for the pre-stimulus (from −200 to 0 ms) interval was conducted separately. In order to test the specificity of the results we repeated the follow-up analysis for all other subscores of the 5D-ASC and the PANSS hallucination item P3. In all analyses, the significance level was set to α = 0.05.

Results

Ketamine-induced psychopathological symptoms

The RM-ANOVA revealed significant main effects of condition (baseline, placebo and ketamine) for PANSS score total (F(2,56) = 79.25, p < 0.001), positive (F(2,56) = 23.47, p < 0.001), negative (F(2,56) = 29.59, p < 0.001], disorganization (F(2,56) = 66.68, p < 0.001), excitement (F(2,56) = 23.28, p < 0.001), and distress (F(2,56) = 30.86, p < 0.001) (Fig. 2a). The same was the case for the PANSS positive hallucination item P3 (F(2,56) = 40.04, p < 0.001) (Fig. 2b). Post-hoc t-tests showed that all subscores of the PANSS as well as the positive item P3 (hallucinations) were significantly increased after ketamine administration in comparison to placebo administration and baseline values. There were no significant differences with respect to any PANSS score and positive item between baseline and placebo condition (Fig. 2). Moreover, 5D-ASC scores (Figure S2), including the AUA-AVD/AVH score (t = 3.05; p = 0.042 after Bonferroni correction; Fig. 2c), were significantly increased after ketamine administration compared to placebo administration. The subgroups (AVD/AVH, non-AVD/AVH) did not differ in any other 5D-ASC subscore (all p > 0.15). The analysis of internal consistency of the AUA-AVD/AVH score revealed a good level of reliability (Cronbach’s α = 0.889).

Fig. 2
figure 2

Bar charts of mean values of the five PANSS subscores (a) and the positive items (b) of the PANSS with error bars representing ±1 standard error. Bar charts of the subscore auditory alterations in the form of auditory verbal distortions and hallucinations (AUA-AVD/AVH) of the 5D-ASC (in %) (c) for each subject in descending order under ketamine administration compared to placebo administration. The black, horizontal line indicates where the median split was conducted. P1 = delusion; P2 = conceptual disorganization; P3 = hallucinations; P4 = excitement; P5 = grandiosity; P6 = suspiciousness/persecution; P7 = hostility. *p < 0.05; **p < 0.01; ***p < 0.001; n = 19

Dichotic listening task performance

Reaction times were significantly increased under ketamine compared to placebo for LE reports (placebo: mean = 2.63 s; SD = 0.31 s; ketamine: mean = 3.20 s; SD = 0.47 s; t = 4.58; p < 0.001) as well as for RE reports (placebo: mean = 2.54 s; SD = 0.28 s; ketamine: mean = 3.15 s; SD = 0.42 s; t = 5.10; p < 0.001). There were no significant differences between ketamine and placebo in LI and error rates (p > 0.179). For detailed information see Table S2.

N100, baseline, and evoked gamma power

At sensor level, auditory presentation of CV-syllables elicited the typical N100 component of the auditory-evoked potential for placebo and ketamine (Figure S3). In addition, time–frequency analysis using complex Morlet wavelet transformation showed the typical auditory-evoked gamma-band response (aeGBR) in the frequency range around 40 Hz after syllable presentation for both conditions (Figure S4). There were no significant difference of the aeGBR power and the N100 potential between ketamine and placebo (p > 0.45). Baseline gamma power was significantly increased by ketamine (F = 9.72, p = 0.006) across all scalp regions (Figure S5). There were no relations between N100, aeGBR or baseline gamma power, and AUA-AVD/AVH.

Functional connectivity by means of lagged phase synchronization (LPS)

There were no significant differences in baseline LPS (−200 to 0 ms) between ketamine and placebo as well as between the AVD/AVH and non-AVD/AVH group, and no significant effect or interaction of ROI in any of the analyses. The three-way Substance × Time × Condition interaction had a significant effect on Gamma Connectivity (F(9, 902.478) = 2.027, p = 0.034).

In order to further clarify this interaction, follow-up LMMs were conducted (see also Supplementary Results) separately for LE and RE reports, with Substance, Time and ROI as fixed factors and Gamma Connectivity as dependent variable. This analysis revealed that the interaction of Time × Substance had a significant effect on Gamma Connectivity for LE reports (F(9,578.560) = 2.605, p = 0.006] (Fig. 3) but not for RE reports (F(9,608.998) = 0.963, p > 0.470), indicating an altered time course of gamma-band connectivity during LE reports under ketamine compared to placebo. Therefore, all subsequent analyses focused on gamma connectivity during LE reports. Subsequent post-hoc pair wise comparison of every time point between placebo and ketamine during LE reports revealed stronger interhemispheric gamma-band connectivity at statistical trend level at 300 ms (t = 1.998, p = 0.061) and 500 ms (t = 1.916, p = 0.071) post-stimulus for ketamine.

Fig. 3
figure 3

Time course of interhemispheric auditory connectivity in the gamma-band (30–100 Hz) between bilateral auditory cortices (BA41 and BA42) during left ear (LE) reports for ketamine (red line) and placebo (blue line) (n = 19). Syllable presentation starts at 0 ms and ends around 500 ms. The quality of gamma-band connectivity was found to be significantly altered under ketamine administration in contrast to placebo. Shaded error bars: ±1 standard error

Functional connectivity differences during LE reports between AVD/AVH and non-AVD/AVH subjects were investigated with a LMM including  Substance, Time and ROIas within-subjects factors, and Group (AVD/AVH vs. non-AVD/AVH) as between-subject factor. This analysis revealed a significant interaction of Substance × Group (F(1,207.690) = 8.151, p = 0.005). Follow-up LMM analyses conducted for each Substance separately showed a significant main effect of group for ketamine (F(1,82.609) = 7.215, p = 0.009) but not for placebo (F(1,79.364) = 1.372, p > 0.245) (Fig. 4), indicating higher gamma-band connectivity for AVD/AVH compared to non-AVD/AVH under ketamine during LE reports. This analysis did not reveal significance for any other 5D-ASC subscore and neither for P3 (p > 0.154), indicating the specificity of the AUA-AVD/AVH score. A positive correlation between the AUA-AVD/AVH score and the mean LPS difference score (r = 0.311, p = 0.194) did not reveal significance, although the correlation coefficient already indicates a medium effect size. There was no significant correlation between baseline gamma power and interhemispheric gamma-band connectivity under ketamine.

Fig. 4
figure 4

Time course of interhemispheric auditory connectivity in the gamma-band (30–100 Hz) between bilateral auditory cortices (BA41 and BA42) during left ear (LE) reports for AVD/AVH (n = 9; red line) and non-AVD/AVH (n = 10; cyan line) subjects under ketamine (a) and under placebo (b) administration. Syllable presentation starts at 0 ms and ends around 500 ms. Shaded error bars: ±1 standard error. Gamma-band connectivity was significantly increased in the AVD/AVH group compared to the non-AVD/AVH group over time under ketamine administration: bar charts of mean lagged phase synchronization (LPS) during LE reports under ketamine (c) and under placebo (d) administration for AVD/AVH (n = 9) and non-AVD/AVH (n = 10; with error bars representing ±1 standard error). **p < 0.01; n.s. = not significant

Discussion

In accordance with our hypothesis, the main findings were that ketamine (1) elicited schizophrenia-like symptoms including AVH, (2) altered interhemispheric gamma-band connectivity during perception of LE syllables, and that (3) enhanced interhemispheric gamma-band connectivity was particularly related to the occurrence of AVD/AVH under ketamine administration.

Currently, there are several models attempting to explain the underlying mechanisms of AVH, including the hypothesis of interhemispheric miscommunication [3, 9]. Several studies using various modalities (DTI, fMRI, and EEG) support the concept that altered connectivity between bilateral auditory areas via the CC is related to the appearance of AVH [3, 6]. Concordant with this, it has been shown that abnormal synchrony of oscillatory activity, notably in the gamma-band range, is associated with schizophrenia, leading to neuropsychiatric symptoms such as AVH [4]. Indeed, several studies have indicated that positive symptoms, particularly AVH, are related to increased oscillatory gamma-band coupling between circumscribed sensory brain areas [11, 45]. Further support was provided by a recent EEG study showing that the emergence of AVH in patients with schizophrenia was particularly related to stronger interhemispheric gamma-band connectivity between bilateral auditory cortices during LE percepts in a DL task [12]. Although there are several lines of evidence concerning the interhemispheric miscommunication hypothesis on the basis of structural and functional findings, there is not much known about the underlying neurochemical aspects.

Schizophrenia has been associated with disturbed high-frequency GBO [17, 18], which are generated by the interaction of fast-spiking PV interneurons and pyramidal neurons via a feedback loop. While ketamine induces similar effects in healthy humans, such as increasing resting-state gamma-power [25], schizophrenia has been linked to deficient NMDAR functioning [46]. However, somatostatin (SST) interneurons may be more sensitive to deficient NMDAR signaling than PV. As a result, reduced SST activity due to deficient NMDAR signaling would increase PV activity and thus increase GBO. Furthermore, SST inhibition has been associated with hyperconnectivity observed in schizophrenia patients [20]. Therefore, impairments in SST neurons might help to understand that deficient NMDAR functioning results in increased functional connectivity. Thus, altered gamma-band coupling between auditory cortices in AVH, as suggested by the interhemispheric miscommunication hypothesis, might be considered in terms of the NMDAR-hypofunction hypothesis of schizophrenia. NMDAR antagonists are known to induce schizophrenia-like symptoms including AVH in healthy subjects [26, 47] and to induce an E/I imbalance that has been identified as a fundamental contributing factor in the generation of GBO [20]. Moreover, E/I imbalance has also been associated with the appearance of AVH in schizophrenia [23]. In line with this, we found that ketamine modified interhemispheric connectivity in the gamma-band range, and further, increased interhemispheric gamma-band connectivity in healthy subjects with AVD/AVH under ketamine administration.

Although in the ketamine literature ketamine-induced AVH are described only intermittently, one might wonder why half of our participants reported AVH and/or distortions. One reason could be that asking specifically for AVD/AVH possibly endorses symptoms that participants would not report spontaneously. Additional reasons could be that AVD/AVH have not been investigated consistently in studies with ketamine or auditory alterations were not described in detail [27]. Bowdle et al [47] have noted that plasma concentrations of ketamine correlate with the item “I heard voices or sounds that were not real” of a visual analog rating scale, but this finding was not elaborated on further. Another study assessed hallucinatory psychopathology only with the PANSS P3 item, reflecting hallucinations in any sensory modality and not necessarily auditory hallucinations [28]. However, this study reported detailed case descriptions of healthy subjects with AVH under ketamine administration and proposed that the occurrence of AVH is crucially dependent on ketamine dose and environment [28]. The PANSS item P3 is a well-established item of detecting any kind of hallucination, such as visual, olfactory, somatic, and auditory hallucinations. As we were particularly interested in auditory alterations similar to AVH in schizophrenia, we used—in addition to the PANSS—the 5D-ASC questionnaire. The 5D-ASC consists of a detailed subscore detecting auditory alterations (AUA subscore) such as auditory verbal hallucinations and non-verbal hallucinations related to sounds. Furthermore, the 5D-ASC was previously shown to be particularly sensitive to the psychological effects of ketamine [27]. In order to approach AVH in schizophrenia, the present study focussed on items of the AUA subscore related to auditory verbal distortions and hallucinations (AUA-AVD/AVH) and not to any other non-verbal auditory hallucinations. Additionally, as it is known that low doses (0.003 mg/kg/min) of ketamine only elicit mild symptoms such as vigilance reduction, but high doses of ketamine (0.005 mg/kg/min) are capable of inducing auditory alterations [29], a high ketamine dose (0.006 mg/kg/min) was administered in the current study.

Investigating the interhemispheric miscommunication hypothesis of AVH specifically, we used a DL task. Steinmann et al. [15] demonstrated that interhemispheric auditory connectivity via the CC is especially required during the perception of LE syllables, that interhemispheric transfer is mediated by synchronized GBO, and further, that increased interhemispheric gamma-band connectivity during conscious perception of the LE syllable has been related to AVH in schizophrenia [12].

In accordance with this, we found altered interhemispheric gamma-band connectivity under high-dose ketamine administration during LE percepts, and that increased interhemispheric gamma-band connectivity is related to the appearance of AUA-AVD/AVH. One might have expected a modified DL performance during ketamine administration. However, the auditory hallucinatory state has been associated with reduced responsiveness to external auditory stimuli [48].

One limitation of the present study is the relatively low spatial accuracy. However, the use of simultaneous EEG and fMRI has proposed sufficient validity of the LORETA approach in general [49, 50]. Moreover, connectivity analysis based on EEG rather than fMRI has the advantage of an excellent temporal accuracy measuring direct neuronal activity in the millisecond-range. In addition, the specific strength of the LPS method is that confounding factors such as volume conduction effects are eliminated, and only physiological connectivity information is thought to remain [40, 41]. The current study shows that the severity of ketamine-induced schizophrenia-like symptoms varies between healthy subjects from no auditory alterations to auditory distortion and AVH. At first glance, this seems to restrain the transfer of the results in healthy volunteers to schizophrenia patients. However, the fact that altered interhemispheric gamma-band connectivity has been shown in both, schizophrenia patients with AVH [12] and healthy volunteers with ketamine-induced AVD/AVH, supports the hypothesis of NMDAR hypofunction as one neurophysiological correlate of AVH in schizophrenia.

In conclusion, the present study demonstrates for the first time that AVD/AVH induced by NMDAR blockade in healthy subjects are related to increased auditory interhemispheric connectivity in the gamma-band frequency range. Thus, the current study supports the hypothesis that increased gamma-band coupling in AVH might be considered in terms of the NMDAR-hypofunction hypothesis of schizophrenia, and provides further evidence for interhemispheric miscommunication due to E/I imbalance as a correlate of AVH. These results have strong implications for future research about both neurophysiological and the neurochemical mechanisms underlying AVH.